Literature DB >> 22072776

Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.

Ritu R Bradley1, Diana M Lynch, Mark J Iampietro, Erica N Borducchi, Dan H Barouch.   

Abstract

The immunogenicity of adenovirus serotype 5 (Ad5) vectors has been shown to be suppressed by neutralizing antibodies (NAbs) directed primarily against the hexon hypervariable regions (HVRs). However, the role of NAbs directed against other capsid components, particularly the adenovirus fiber, remains unclear. Here we show that Ad5 NAbs target both hexon and fiber following vaccination and natural infection. Utilizing neutralization assays with capsid chimeric vectors, we observed that NAb responses to hexon appeared dominant and NAb responses against fiber were subdominant in sera from vaccinated mice, vaccinated humans, and naturally exposed humans. A novel chimeric Ad5 vector in which both the hexon HVRs and the fiber knob were exchanged nearly completely evaded Ad5-specific NAbs both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072776      PMCID: PMC3255879          DOI: 10.1128/JVI.06254-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  15 in total

1.  Hexon gene switch strategy for the generation of chimeric recombinant adenovirus.

Authors:  Rima Youil; Timothy J Toner; Qin Su; Minchun Chen; Aimin Tang; Andrew J Bett; Danilo Casimiro
Journal:  Hum Gene Ther       Date:  2002-01-20       Impact factor: 5.695

2.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Authors:  Diane M Roberts; Anjali Nanda; Menzo J E Havenga; Peter Abbink; Diana M Lynch; Bonnie A Ewald; Jinyan Liu; Anna R Thorner; Patricia E Swanson; Darci A Gorgone; Michelle A Lifton; Angelique A C Lemckert; Lennart Holterman; Bing Chen; Athmanundh Dilraj; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Dan H Barouch
Journal:  Nature       Date:  2006-04-16       Impact factor: 49.962

4.  Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor.

Authors:  Christopher J Cohen; Zhi Quan Xiang; Guang-Ping Gao; Hildegund C J Ertl; James M Wilson; Jeffrey M Bergelson
Journal:  J Gen Virol       Date:  2002-01       Impact factor: 3.891

5.  International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.

Authors:  Dan H Barouch; Sandra V Kik; Gerrit J Weverling; Rebecca Dilan; Sharon L King; Lori F Maxfield; Sarah Clark; David Ng'ang'a; Kara L Brandariz; Peter Abbink; Faruk Sinangil; Guy de Bruyn; Glenda E Gray; Surita Roux; Linda-Gail Bekker; Athmanundh Dilraj; Hannah Kibuuka; Merlin L Robb; Nelson L Michael; Omu Anzala; Pauli N Amornkul; Jill Gilmour; John Hural; Susan P Buchbinder; Michael S Seaman; Raphael Dolin; Lindsey R Baden; Angela Carville; Keith G Mansfield; Maria G Pau; Jaap Goudsmit
Journal:  Vaccine       Date:  2011-05-25       Impact factor: 3.641

6.  Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.

Authors:  Shawn M Sumida; Diana M Truitt; Angelique A C Lemckert; Ronald Vogels; Jerome H H V Custers; Marylyn M Addo; Shahin Lockman; Trevor Peter; Fred W Peyerl; Michael G Kishko; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Myron Essex; Bruce D Walker; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

7.  Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.

Authors:  H Gahéry-Ségard; F Farace; D Godfrin; J Gaston; R Lengagne; T Tursz; P Boulanger; J G Guillet
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

8.  Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies.

Authors:  Jinyan Liu; Bonnie A Ewald; Diana M Lynch; Anjali Nanda; Shawn M Sumida; Dan H Barouch
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

9.  Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.

Authors:  Saw See Hong; Nagy A Habib; Laure Franqueville; Steen Jensen; Pierre A Boulanger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Authors:  Dan H Barouch; Maria G Pau; Jerome H H V Custers; Wouter Koudstaal; Stefan Kostense; Menzo J E Havenga; Diana M Truitt; Shawn M Sumida; Michael G Kishko; Janelle C Arthur; Birgit Korioth-Schmitz; Michael H Newberg; Darci A Gorgone; Michelle A Lifton; Dennis L Panicali; Gary J Nabel; Norman L Letvin; Jaap Goudsmit
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

View more
  53 in total

Review 1.  Getting genetic access to natural adenovirus genomes to explore vector diversity.

Authors:  Wenli Zhang; Anja Ehrhardt
Journal:  Virus Genes       Date:  2017-07-15       Impact factor: 2.332

2.  Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.

Authors:  Joseph T Bruder; Ping Chen; Elena Semenova; Charlie A Thomas; Svetlana Konovalova; Greg Ekberg; Damodar Ettyreddy; Duncan McVey; Jason G Gall; C Richter King; Douglas E Brough
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

3.  The effect of fiber truncations on the stability of adenovirus type 5.

Authors:  Grit Kupgan; Danielle C Hentges; Nathan J Muschinske; William D Picking; Wendy L Picking; Joshua D Ramsey
Journal:  Mol Biotechnol       Date:  2014-11       Impact factor: 2.695

Review 4.  Vaccine development for human mastadenovirus.

Authors:  Shiying Chen; Xingui Tian
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

5.  Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus.

Authors:  Dongming Zhou; Te-Lang Wu; Kristel L Emmer; Raj Kurupati; Steven Tuyishime; Yan Li; Wynetta Giles-Davis; Xiangyang Zhou; Zhiquan Xiang; Qin Liu; Sarah J Ratcliffe; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

6.  Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.

Authors:  Linlin Gu; Anitra L Farrow; Alexandre Krendelchtchikov; Qiana L Matthews
Journal:  J Vis Exp       Date:  2015-05-06       Impact factor: 1.355

7.  First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).

Authors:  Lindsey R Baden; Stephen R Walsh; Michael S Seaman; Jennifer A Johnson; Robert P Tucker; Jane A Kleinjan; Jon A Gothing; Brian A Engelson; Brittany R Carey; Avinash Oza; Shringkhala Bajimaya; Lauren Peter; Chelsea Bleckwehl; Peter Abbink; Maria G Pau; Mo Weijtens; Meghan Kunchai; Edith M Swann; Mark Wolff; Raphael Dolin; Dan H Barouch
Journal:  J Infect Dis       Date:  2014-04-08       Impact factor: 5.226

8.  A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.

Authors:  Monica Cabrera-Mora; Jairo Andres Fonseca; Balwan Singh; Chunxia Zhao; Natalia Makarova; Igor Dmitriev; David T Curiel; Jerry Blackwell; Alberto Moreno
Journal:  J Immunol       Date:  2016-08-29       Impact factor: 5.422

Review 9.  Development of adenovirus capsid proteins for targeted therapeutic delivery.

Authors:  Lali K Medina-Kauwe
Journal:  Ther Deliv       Date:  2013-02

Review 10.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.